HealthScout Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 
 
 Printer Friendly  Send to a Friend

New MS Therapies Show Promise

But the side effects of one drug require much more research, researchers say


Related Encyclopedia
 border=
Acoustic Neurinoma
Bell's Palsy
Brain and Spinal Cord Magnetic Resonance Imaging
Brain Tumors
More...

Related Healthscout Videos
 border=
New Drugs That Could Stop MS
New Therapy for Stroke Patients
Mapping the Brain     
Hope for MS
More...

Related Drug Information
 border=
Adderal XR
Concerta
Coumadin
Depakote
More...

Related News Articles
 border=
Family History of Aneurysm Raises Stroke Risk for Smokers
Study of Everest Climbers Questions Oxygen Use
Childhood Trauma Tied to Chronic Fatigue Syndrome
Brains of Bulimia Patients Wired Differently
More...

THURSDAY, Oct. 23 (HealthDay News) -- Two medications may prove to be advances in the treatment of multiple sclerosis, researchers say.

In one study, an experimental drug called oral fumarate (BG00012) substantially reduced symptoms in patients with relapsing-remitting multiple sclerosis, according to a phase II clinical trial by European and North American researchers.

Text Continues Below



And in a second trial, researchers found that the leukemia drug alemtuzumab (Campath) was about 70 percent more effective than another drug already widely used to treat MS. However, alemtuzumab also had significant side effects, including bleeding disorders, a greater risk of thyroid disease, and infections. This prompted experts to say that much more research is needed before alemtuzumab can be prescribed to treat multiple sclerosis.

Multiple sclerosis is a nervous system disease that affects the brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects nerve cells. This damage slows or blocks messages between the brain and the body, according to the U.S. National Library of Medicine.

Symptoms of the disease can include visual disturbances; muscle weakness; trouble with coordination and balance; sensations such as numbness, prickling, or "pins and needles;" and thinking and memory problems.

It's not known what causes multiple sclerosis. It may be an autoimmune disease, which happens when the body attacks itself. MS affects women more than men, and it often begins between the ages of 20 and 40. An estimated 400,000 Americans have the disease. Usually, the disease is mild, but some people lose the ability to write, speak or walk. There's no cure for MS, but medicines may slow it down and help control symptoms, according to the National Library of Medicine.

The 24-week study of BG00012 included 257 patients, ages 18 to 55, who were randomly assigned to receive either 120 milligrams of BG00012 once a day (64 patients), 120 milligrams three times a day (64 patients), 240 milligrams three times a day (64 patients), or a placebo (65 patients). The patients were assessed at weeks 12, 16, 20 and 24.

Page:  1 | 2 | 3 | Next >>

-- Robert Preidt

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 10/24/2008

Related Links
 border=
From Healthscout's partner site on chronic pain, ChronicPainConnection.com
Find ways to get chronic pain relief!
Find a right treatment for your chronic pain
Join our community - your chronic pain support group.




SOURCE: The Lancet, news release, Oct. 23, 2008; New England Journal of Medicine, Oct. 23, 2008


Healthscout Search
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Resources
Healthscout News
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
Newsletter Subscription
News Archive
PR Newswire News Video Releases
Privacy Policy

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service